Generic Name and Formulations:
Trivalent inactivated "split virus" influenza vaccine (Types A and B); formulation changes annually; susp for IM inj; contains thimerosal.
Novartis Pharmaceuticals Corp
Indications for FLUVIRIN:
Adults and Children:
<4yrs: not recommended. Each dose is 0.5mL IM. 4–8yrs: 2 doses at least 1 month apart for 1st immunization, otherwise 1 dose per season. >9yrs: 1 dose/season. Infants and young children: give in anterolateral thigh; older: give in deltoid muscle.
Allergy to egg proteins. Life-threatening reaction to any previous flu vaccine.
Use current formulation only. Guillain-Barre syndrome within 6 weeks of previous flu vaccine. Immunosuppressed. Have epinephrine inj (1:1000) available. Pregnancy (Cat.C). Nursing mothers.
Concomitant vaccines: insufficient data (see literature). Immunosuppressants (eg, radiation, chemotherapy, high-dose steroids) may result in suboptimal response.
Local reactions, headache, fever, malaise, fatigue, myalgia.
Multidose vial (5mL)—1
Single-dose prefilled syringes (0.5mL)—10
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|